OMER Quote, Financials, Valuation and Earnings

Chimerix has a net margin of -- compared to Omeros's net margin of -40270.18%. Omeros's return on equity of -- beat Chimerix's return on equity of -56.65%.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 514.34%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.12%. Given that Omeros has higher upside potential than Chimerix, analysts believe Omeros is more attractive than Chimerix.

Omeros has a beta of 2.352, which suggesting that the stock is 135.194% more volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than Chimerix quarterly revenues of $57K. Omeros's net income of -$32.2M is lower than Chimerix's net income of -$23M. Notably, Omeros's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Omeros's net margin of -49.65%. Omeros's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 514.34%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 73.47%. Given that Omeros has higher upside potential than NovaBay Pharmaceuticals, analysts believe Omeros is more attractive than NovaBay Pharmaceuticals.

Omeros has a beta of 2.352, which suggesting that the stock is 135.194% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Omeros's net income of -$32.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Omeros's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus 0.13x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Omeros's net margin of -2357.27%. Omeros's return on equity of -- beat Palatin Technologies's return on equity of --.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 514.34%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Omeros, analysts believe Palatin Technologies is more attractive than Omeros.

Omeros has a beta of 2.352, which suggesting that the stock is 135.194% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Omeros's net income of -$32.2M is lower than Palatin Technologies's net income of -$2.4M. Notably, Omeros's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -- compared to Omeros's net margin of --. Omeros's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 514.34%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 2464.1%. Given that ZyVersa Therapeutics has higher upside potential than Omeros, analysts believe ZyVersa Therapeutics is more attractive than Omeros.

Omeros has a beta of 2.352, which suggesting that the stock is 135.194% more volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than ZyVersa Therapeutics quarterly revenues of --. Omeros's net income of -$32.2M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, Omeros's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.